Concepts (137)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Aging | 8 | 2017 | 190 | 0.880 |
Why?
|
| Longitudinal Studies | 9 | 2019 | 246 | 0.720 |
Why?
|
| Cognition | 6 | 2018 | 203 | 0.590 |
Why?
|
| Brain | 5 | 2019 | 197 | 0.560 |
Why?
|
| Biostatistics | 1 | 2016 | 3 | 0.500 |
Why?
|
| Models, Statistical | 1 | 2016 | 27 | 0.500 |
Why?
|
| Cognitive Dysfunction | 5 | 2019 | 149 | 0.480 |
Why?
|
| Female | 19 | 2019 | 1644 | 0.450 |
Why?
|
| Male | 18 | 2019 | 1781 | 0.430 |
Why?
|
| Humans | 20 | 2019 | 2822 | 0.390 |
Why?
|
| Cognition Disorders | 5 | 2017 | 163 | 0.390 |
Why?
|
| Aged | 15 | 2019 | 898 | 0.370 |
Why?
|
| DNA-Binding Proteins | 5 | 2019 | 68 | 0.340 |
Why?
|
| Aged, 80 and over | 12 | 2019 | 540 | 0.320 |
Why?
|
| Alzheimer Disease | 5 | 2019 | 236 | 0.280 |
Why?
|
| Hippocampus | 3 | 2019 | 41 | 0.270 |
Why?
|
| Cognitive Aging | 2 | 2018 | 24 | 0.260 |
Why?
|
| Neurodegenerative Diseases | 2 | 2018 | 32 | 0.260 |
Why?
|
| Dementia | 2 | 2017 | 68 | 0.250 |
Why?
|
| Intracranial Aneurysm | 2 | 2018 | 7 | 0.230 |
Why?
|
| Neuropsychological Tests | 7 | 2019 | 223 | 0.220 |
Why?
|
| Lewy Bodies | 3 | 2019 | 37 | 0.200 |
Why?
|
| Perception | 2 | 2019 | 20 | 0.190 |
Why?
|
| Memory, Episodic | 2 | 2019 | 21 | 0.180 |
Why?
|
| Ventriculostomy | 2 | 2012 | 2 | 0.180 |
Why?
|
| Disease Outbreaks | 2 | 2013 | 9 | 0.180 |
Why?
|
| Middle Aged | 7 | 2018 | 756 | 0.170 |
Why?
|
| Disease Progression | 2 | 2019 | 95 | 0.160 |
Why?
|
| Neurofibrillary Tangles | 2 | 2017 | 25 | 0.160 |
Why?
|
| Amyloid beta-Peptides | 2 | 2017 | 27 | 0.160 |
Why?
|
| Logistic Models | 2 | 2016 | 59 | 0.150 |
Why?
|
| Memory, Short-Term | 1 | 2019 | 23 | 0.150 |
Why?
|
| Learning | 1 | 2018 | 20 | 0.140 |
Why?
|
| Ambulatory Care | 1 | 2017 | 9 | 0.130 |
Why?
|
| Chronic Disease | 1 | 2017 | 28 | 0.130 |
Why?
|
| Neuropathology | 1 | 2017 | 15 | 0.130 |
Why?
|
| Hospitalization | 1 | 2017 | 47 | 0.130 |
Why?
|
| Likelihood Functions | 1 | 2016 | 10 | 0.130 |
Why?
|
| Data Interpretation, Statistical | 1 | 2016 | 11 | 0.130 |
Why?
|
| Linear Models | 1 | 2016 | 34 | 0.120 |
Why?
|
| Computer Simulation | 1 | 2016 | 37 | 0.120 |
Why?
|
| Brain Chemistry | 1 | 2016 | 11 | 0.120 |
Why?
|
| Depressive Disorder, Major | 1 | 2016 | 13 | 0.120 |
Why?
|
| Body Mass Index | 1 | 2016 | 64 | 0.120 |
Why?
|
| Factor Analysis, Statistical | 1 | 2015 | 9 | 0.120 |
Why?
|
| Depression | 1 | 2016 | 57 | 0.120 |
Why?
|
| Thiazolidinediones | 1 | 2014 | 4 | 0.110 |
Why?
|
| Central Nervous System Agents | 1 | 2014 | 4 | 0.110 |
Why?
|
| Pyridines | 1 | 2014 | 12 | 0.110 |
Why?
|
| Influenza A Virus, H9N2 Subtype | 1 | 2013 | 1 | 0.100 |
Why?
|
| Rural Population | 1 | 2013 | 2 | 0.100 |
Why?
|
| Antibodies, Viral | 1 | 2013 | 5 | 0.100 |
Why?
|
| Influenza, Human | 1 | 2013 | 5 | 0.100 |
Why?
|
| Sclerosis | 3 | 2019 | 25 | 0.100 |
Why?
|
| Third Ventricle | 1 | 2012 | 1 | 0.090 |
Why?
|
| Neurosurgical Procedures | 1 | 2012 | 3 | 0.090 |
Why?
|
| Adult | 4 | 2018 | 759 | 0.090 |
Why?
|
| Stents | 1 | 2010 | 6 | 0.090 |
Why?
|
| Postoperative Hemorrhage | 1 | 2010 | 2 | 0.090 |
Why?
|
| Adenoviridae Infections | 1 | 2009 | 1 | 0.080 |
Why?
|
| Adenoviruses, Human | 1 | 2009 | 1 | 0.080 |
Why?
|
| Risk Factors | 3 | 2018 | 263 | 0.070 |
Why?
|
| Autopsy | 2 | 2019 | 39 | 0.070 |
Why?
|
| Young Adult | 3 | 2013 | 179 | 0.070 |
Why?
|
| Cohort Studies | 2 | 2018 | 222 | 0.060 |
Why?
|
| Antibodies, Bacterial | 1 | 2006 | 1 | 0.060 |
Why?
|
| Deer | 1 | 2006 | 1 | 0.060 |
Why?
|
| Ehrlichiosis | 1 | 2006 | 1 | 0.060 |
Why?
|
| Anaplasma phagocytophilum | 1 | 2006 | 1 | 0.060 |
Why?
|
| Chicago | 2 | 2017 | 148 | 0.060 |
Why?
|
| Aneurysm, Ruptured | 2 | 2018 | 6 | 0.060 |
Why?
|
| Magnetic Resonance Imaging | 2 | 2016 | 77 | 0.050 |
Why?
|
| Age Factors | 2 | 2016 | 84 | 0.050 |
Why?
|
| Treatment Outcome | 2 | 2014 | 182 | 0.050 |
Why?
|
| Retrospective Studies | 2 | 2012 | 165 | 0.040 |
Why?
|
| Child, Preschool | 2 | 2012 | 118 | 0.040 |
Why?
|
| Child | 2 | 2012 | 190 | 0.040 |
Why?
|
| Enzyme-Linked Immunosorbent Assay | 2 | 2013 | 14 | 0.040 |
Why?
|
| Multivariate Analysis | 1 | 2018 | 17 | 0.040 |
Why?
|
| Case-Control Studies | 1 | 2018 | 61 | 0.040 |
Why?
|
| Statistics as Topic | 1 | 2017 | 18 | 0.030 |
Why?
|
| Animals | 2 | 2013 | 978 | 0.030 |
Why?
|
| Anisotropy | 1 | 2016 | 11 | 0.030 |
Why?
|
| Diffusion Tensor Imaging | 1 | 2016 | 8 | 0.030 |
Why?
|
| Image Processing, Computer-Assisted | 1 | 2016 | 24 | 0.030 |
Why?
|
| Brain Stem | 1 | 2016 | 5 | 0.030 |
Why?
|
| Cerebral Cortex | 1 | 2016 | 25 | 0.030 |
Why?
|
| Models, Psychological | 1 | 2015 | 4 | 0.030 |
Why?
|
| Statistics, Nonparametric | 1 | 2015 | 21 | 0.030 |
Why?
|
| Psychiatric Status Rating Scales | 1 | 2015 | 33 | 0.030 |
Why?
|
| Reaction Time | 1 | 2015 | 28 | 0.030 |
Why?
|
| Memory | 1 | 2015 | 43 | 0.030 |
Why?
|
| Follow-Up Studies | 1 | 2015 | 139 | 0.030 |
Why?
|
| Glucose | 1 | 2014 | 4 | 0.030 |
Why?
|
| Radiopharmaceuticals | 1 | 2014 | 11 | 0.030 |
Why?
|
| Mental Status Schedule | 1 | 2014 | 25 | 0.030 |
Why?
|
| Fluorodeoxyglucose F18 | 1 | 2014 | 11 | 0.030 |
Why?
|
| Brain Mapping | 1 | 2014 | 23 | 0.030 |
Why?
|
| Positron-Emission Tomography | 1 | 2014 | 15 | 0.030 |
Why?
|
| Double-Blind Method | 1 | 2014 | 46 | 0.030 |
Why?
|
| Cambodia | 1 | 2013 | 1 | 0.030 |
Why?
|
| Occupational Exposure | 1 | 2013 | 1 | 0.030 |
Why?
|
| Surveys and Questionnaires | 1 | 2013 | 138 | 0.020 |
Why?
|
| Prospective Studies | 1 | 2013 | 197 | 0.020 |
Why?
|
| Central Nervous System Infections | 1 | 2012 | 1 | 0.020 |
Why?
|
| Optic Chiasm | 1 | 2012 | 1 | 0.020 |
Why?
|
| Hydrocephalus | 1 | 2012 | 2 | 0.020 |
Why?
|
| Preoperative Period | 1 | 2012 | 5 | 0.020 |
Why?
|
| Survival Analysis | 1 | 2012 | 7 | 0.020 |
Why?
|
| Kaplan-Meier Estimate | 1 | 2012 | 11 | 0.020 |
Why?
|
| Treatment Failure | 1 | 2012 | 11 | 0.020 |
Why?
|
| Analysis of Variance | 1 | 2012 | 30 | 0.020 |
Why?
|
| Predictive Value of Tests | 1 | 2012 | 48 | 0.020 |
Why?
|
| Algorithms | 1 | 2012 | 52 | 0.020 |
Why?
|
| Infant | 1 | 2012 | 122 | 0.020 |
Why?
|
| Adolescent | 1 | 2012 | 241 | 0.020 |
Why?
|
| Ventriculoperitoneal Shunt | 1 | 2010 | 1 | 0.020 |
Why?
|
| Platelet Aggregation Inhibitors | 1 | 2010 | 7 | 0.020 |
Why?
|
| Risk | 1 | 2010 | 43 | 0.020 |
Why?
|
| Subarachnoid Hemorrhage | 1 | 2010 | 5 | 0.020 |
Why?
|
| Sex Factors | 1 | 2010 | 68 | 0.020 |
Why?
|
| Endovascular Procedures | 1 | 2010 | 14 | 0.020 |
Why?
|
| Tomography, X-Ray Computed | 1 | 2010 | 83 | 0.020 |
Why?
|
| Connecticut | 1 | 2009 | 1 | 0.020 |
Why?
|
| Polymorphism, Restriction Fragment Length | 1 | 2009 | 1 | 0.020 |
Why?
|
| DNA Fingerprinting | 1 | 2009 | 1 | 0.020 |
Why?
|
| Molecular Epidemiology | 1 | 2009 | 2 | 0.020 |
Why?
|
| DNA, Viral | 1 | 2009 | 5 | 0.020 |
Why?
|
| Arachnid Vectors | 1 | 2006 | 1 | 0.020 |
Why?
|
| Disease Reservoirs | 1 | 2006 | 1 | 0.020 |
Why?
|
| Zoonoses | 1 | 2006 | 1 | 0.020 |
Why?
|
| Seroepidemiologic Studies | 1 | 2006 | 1 | 0.020 |
Why?
|
| Sentinel Surveillance | 1 | 2006 | 1 | 0.020 |
Why?
|
| Ixodes | 1 | 2006 | 1 | 0.020 |
Why?
|
| Animals, Wild | 1 | 2006 | 2 | 0.020 |
Why?
|
| Iowa | 1 | 2006 | 2 | 0.020 |
Why?
|
| Blotting, Western | 1 | 2006 | 23 | 0.020 |
Why?
|